Uniclar

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Uniclar

Property Description
Active Ingredient Mometasone Furoate
Form Aqueous Nasal Spray, Cream, Ointment, Lotion
Pharmacological Class Corticosteroid (Glucocorticoid)
Common Use Anti-inflammatory and Antiallergic relief
Origin Synthetic

Uniclar is a medicinal preparation whose active ingredient is Mometasone Furoate, a potent, synthetic corticosteroid. This compound is classified specifically as a glucocorticoid, which is a type of steroid chemically engineered to replicate the anti-inflammatory and immunosuppressive actions of certain hormones produced naturally by the body. Mometasone Furoate demonstrates a strong receptor binding affinity, which contributes to its high potency when used topically.

Composition: Forms and Base Components

Uniclar is available for localized use through two primary routes of administration: nasal and topical/dermal, determined by the specific formulation chosen. The drug is supplied as an aqueous nasal spray for administration directly to the nasal passages, or as various topical/dermal preparations, including a cream, ointment, and lotion, for precise application to the skin. The core composition involves the active substance dispersed within an appropriate base/vehicle (an aqueous solution or an emulsifying base), ensuring delivery to the target tissue with minimal systemic exposure.

General Purpose and Core Anti-Inflammatory Action

The general purpose of Uniclar is to provide concentrated anti-inflammatory relief by suppressing the body's localized immune response. Operating as a glucocorticoid, Mometasone Furoate acts to modulate the cellular processes that cause inflammation, effectively interrupting the signals that perpetuate tissue reaction. The primary therapeutic function of this substance is its potent local anti-inflammatory activity. This means the medicine generally helps to manage the physical symptoms associated with various inflammatory processes, such as localized swelling, redness, irritation, and persistent itching.

What side effects are possible with Uniclar?

Possible Side Effects and Safety Information for Uniclar (Desloratadine)

Adverse Reaction Scope

Clinical trials indicate that the most common side effects (occurring in 1% to 10% of patients) reported more frequently than placebo are fatigue, dry mouth, and headache. Other common, though less frequent, reports include somnolence, dizziness, nausea, and pharyngitis. The affected system-organ classes primarily involve the Nervous System and Gastrointestinal System.

Serious and Clinically Significant Reactions

Very rare (less than 0.01%) but serious adverse reactions reported from post-marketing surveillance include hypersensitivity reactions (e.g., anaphylaxis, angioedema, dyspnea, rash, and urticaria), hepatitis, and seizures. Other very rare events include tachycardia, palpitations, and psychomotor hyperactivity. Due to individual variation in response, which may include somnolence, caution is advised before driving or operating machinery until the individual response to the medication is known.

Population-Specific Safety Considerations

Uniclar is contraindicated in patients with known hypersensitivity to the active substance (desloratadine), to any excipients, or to loratadine. Use requires caution in patients with severe renal or hepatic impairment, as the exposure to the drug may be increased in these groups, and dosage adjustment (e.g., 5 mg every other day) may be necessary. Caution is also advised in patients with a medical or familial history of seizures.

Desloratadine should be avoided during pregnancy and a decision must be made regarding discontinuation of breastfeeding or therapy, as the drug passes into breast milk.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Uniclar (Mometasone Furoate) primarily addresses the risks associated with chronic overuse or prolonged application of dosages higher than recommended. Acute, single-event overdose is generally classified as a non-severe event and is documented as unlikely to require specific therapeutic intervention beyond observation.

The manifestations of chronic overdose result from systemic absorption of the corticosteroid. Documented presentations include signs of hypercorticism, often referred to as Cushingoid features, and suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis. Metabolic changes such as hyperglycemia and glucosuria may also be present.

Required Emergency Action

A severe outcome noted in regulatory labeling is glucocorticosteroid insufficiency, which may manifest following the cessation of chronic high-dose therapy. This condition requires immediate medical attention. If signs of insufficiency occur, official emergency statements confirm that supplemental systemic corticosteroids are required for management. Procedural instructions for documented HPA axis suppression involve the gradual withdrawal of the drug or substitution with a less potent agent. Pediatric patients are listed as being at a greater risk of HPA axis suppression due to their body surface area to mass ratio.

Therapeutic Uses of Uniclar

What Uniclar Treats: Main Uses and Benefits

Uniclar is applied across domains where additional symptomatic support is needed, particularly for managing symptom clusters that may become intense or disruptive. The medication is commonly used to help with symptoms related to systemic imbalance and inflammatory or irritative states.

The medicine is relevant in contexts marked by increased discomfort or tension, especially in conditions involving episodic or fluctuating manifestations where symptoms interfere with daily functioning. It is often used during phases when symptoms become temporarily overwhelming. This symptomatic assistance is relevant for easing symptoms in scenarios where symptoms escalate temporarily, and provides support that helps ease the overall symptom burden.

“This is commonly used in clinical settings that involve acute or unstable symptom patterns, when short-term symptomatic assistance is needed.”

Quick Fact: Relief for Symptomatic Discomfort

This support helps patients cope more steadily with symptom fluctuations and contributes to improved comfort during periods of heightened symptoms, assisting with maintaining functional stability when symptoms interfere with routine activities.

Regulatory References

  1. European Medicines Agency (EMA) product information

Eligibility and Restrictions for Use

Who Can and Cannot Use Uniclar?

The eligibility for using Uniclar (Mometasone Furoate) is strictly defined by regulatory documents and depends on the formulation and patient status.

Contraindications (Who Must Not Use)

Uniclar is contraindicated in patients with a known hypersensitivity to Mometasone Furoate or any of the product ingredients. The nasal spray must not be used by individuals with an untreated localized nasal infection (e.g., Herpes simplex) or those who have had recent nasal surgery or trauma until healing is complete. Topical preparations are contraindicated for use on specific skin conditions such as facial rosacea and certain active skin infections.


Age-Based Eligibility and Restrictions

Formulation Minimum Approved Age Safety Not Established In
Aqueous Nasal Spray 2 to 3 years (varies by region) Children under 2 or 3 years; Adolescents under 18 for nasal polyposis.
Topical Preparations 2 years of age Children below 2 years of age.

Conditional Use and Special Populations

Use of Uniclar requires caution and monitoring in patients with conditions such as tuberculosis, systemic infections, glaucoma, cataracts, or hepatic impairment. Use during pregnancy is generally not recommended unless the potential maternal benefit justifies the potential risk, as documented in official regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

It is important to inform your doctor or pharmacist about all prescription, over-the-counter, and herbal medicines you are currently taking or plan to take, as Uniclar (mometasone furoate nasal spray) can interact with certain substances. While systemic absorption of Uniclar is low, certain interactions, particularly with potent inhibitors of the enzyme CYP3A4, are possible. This enzyme is involved in the metabolism of many medicines, including mometasone.

Simultaneous use of Uniclar with potent CYP3A4 inhibitors may lead to increased plasma concentrations of mometasone, potentially raising the risk of systemic corticosteroid side effects. Examples of such inhibitors include, but are not limited to, ketoconazole and itraconazole.

Type of Interaction Potentially Interacting Substance Potential Effect
Drug-Drug CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole) Increased mometasone concentration and systemic side effects.

Other Considerations

Tell your healthcare provider if you are taking any other corticosteroid-containing medicines, including other nasal sprays, asthma inhalers, or oral corticosteroids. Combining these products may increase the overall systemic corticosteroid burden, which can suppress the body's natural hormone production (adrenal suppression). Your doctor will assess whether a dose adjustment or increased monitoring is necessary for safe use.

Mechanism of Action

Uniclar (Mometasone Furoate) exerts its influence by engaging two distinct, yet interconnected, mechanistic domains: the core genomic suppression of inflammatory signals and the rapid modulation of the tissue environment.

Genomic Suppression of Inflammatory Gene Expression

The drug's central mechanism involves agonism of the cytosolic Glucocorticoid Receptor ( GR), which then translocates to the cell nucleus. This activated complex directly regulates the cell's genetic program, notably through Transrepression of pro-inflammatory transcription factors like NF-kappa B. This action is a key regulatory step that limits the fundamental production of inflammatory chemicals, contributing to a reduction of the inflammatory response at the tissue level.

Inhibition of Mediator Cascades and Vascular Modulation

In addition to genomic action, Mometasone Furoate modifies the Arachidonic Acid Cascade by promoting proteins like Lipocortin-1, which inhibits the PLA2 enzyme. This blocks the synthesis of chemical mediators such as prostaglandins and leukotrienes. This cascade effect is coupled with the mechanism's ability to cause localized vasoconstriction, which together results in the physiological consequence of decreasing fluid extravasation and modulating local tissue volume in the targeted tissue.

Mechanism Dynamics and Temporal Constraint

The anti-inflammatory effect is dependent on the genomic mechanism, which requires the process of gene transcription and subsequent protein synthesis. This inherent temporal constraint dictates that the maximal physiological effect builds up gradually over hours to days. This dynamic results in a sustained modulation of the physiological response.

Dosage and Administration Information

Instruction Map: How to use Uniclar — Standard Administration Guidelines

This map structures the high-level administration rules for Mometasone Furoate (Uniclar), focusing on procedural usage patterns.


Administration Scope

Instruction Detail
Route of administration: Intranasal (for the spray formulation) or Topical/Dermal (for the cream, ointment, and lotion).
Dosing schedule: Nasal: Standard adult dose is 2 sprays (100 mcg) in each nostril once daily. Max dose is 400 mcg daily for certain uses. Topical: A thin film applied to the affected skin area once daily.
Preparation requirements (if applicable): The nasal spray device must be shaken well before each use and requires priming (e.g., 10 actuations) prior to first use.
Age-group administration rules: Children (2 to 11 years) Nasal: 1 spray (50 mcg) in each nostril once daily. Children (less than 2 years) Topical: Use is generally not recommended.
Missed-dose rules: If a dose is missed, continue with the next scheduled dose; the dose should not be doubled.
Special procedural conditions: Topical use must not involve occlusive dressings unless specifically instructed. Topical preparations are not for ophthalmic use.

Instruction Classifications (High-Level)

Classification Detail
Administration method type: Topical and Inhaled/Intranasal (Local administration).
Frequency pattern: Primarily Once daily; Twice daily is used for maximum dosage in certain nasal indications.
Use-context constraints: Constraints are defined by dose limits, duration limits (e.g., 5 days for facial use), and site limitations.

Resulting Procedural Structure

Established step sequence:

  • Select the appropriate administration route (Intranasal or Topical) based on the prescribed formulation.
  • For the nasal spray, shake the bottle and ensure the device is properly primed before administration.
  • Administer the fixed dose unit to the specified target area once daily (or twice daily, if instructed).
  • Maintain the prescribed frequency and duration, ceasing use when appropriate or upon professional reassessment.
  • Do not double the dose if an application is missed.

Connection to the overall use protocol:

These instructions establish a structured protocol that dictates the method and frequency of administering the Mometasone Furoate formulations. This protocol relies on device preparation steps and fixed-dose units to achieve accurate, localized delivery via the two distinct routes. The use schedule is defined by a primary once-daily frequency and is constrained by specified total daily dosage and use durations.

Recent Clinical Evidence

Research Evidence for Nasal Spray Formulations

This section summarizes the structure of clinical evidence, primarily Randomized Controlled Trials (RCTs) and meta-analyses, supporting the evaluation of the nasal spray for inflammatory conditions affecting the nose.

The active ingredient in Uniclar, Mometasone Furoate, was observed in a large number of clinical trials to examine the measurements when delivered as a nasal spray. This research structure explores how symptoms were measured and tracked over time in the observed populations.

Studies for Allergic Rhinitis (Seasonal and Perennial)

Research has examined the nasal spray for use in conditions characterized by fluctuating or episodic manifestations, such as both seasonal and perennial allergic rhinitis. Studies included a wide range of individuals, from adults to children as young as 3 or 6 years old. Outcomes was studied for patient-reported experiences related to inflammation, such as nasal congestion, runny nose, itching, and sneezing.

Findings from the body of evidence describe the measurements of patient-reported outcomes and measured symptom variability during the study period. For perennial rhinitis, some long-term studies, lasting up to one year, was observed in to monitor symptom patterns. The time required to reach the most notable measurement change was observed in some studies to be variable.

Studies for Nasal Polyposis

For nasal polyposis, a condition studied for its association with functional imbalance, the evidence was evaluated in moderate-term clinical trials typically lasting around four months. These studies included only adult populations and focused on objective measurements of polyp size and patient-reported outcomes describing perceived discomfort related to breathing.

Long-Term Evidence and Evidence Gaps

The research structure for the nasal spray includes some long-term studies up to one year. Conversely, the evidence for the topical forms is overwhelmingly limited to short-term follow-up durations, typically 2 to 3 weeks. Long-term effects are not fully established for the continuous application of the topical forms, particularly in pediatric populations.

Frequently Asked Questions (FAQ)

Common questions about Uniclar (FAQ)

Q: Is Uniclar used for things other than its main approved uses?

A: According to official prescribing information, Uniclar is approved for the treatment of specific conditions, such as allergic rhinitis and nasal polyposis. Official documents define the scope of its use, and the medicine's documented purpose is solely based on these approved indications.


Q: Can I stop taking Uniclar suddenly, or does it need to be done gradually?

A: Regulatory documents typically indicate that abrupt discontinuation of the medicine may be inadvisable, especially after it has been used for a prolonged time. A gradual process may be recommended to minimize the possibility of withdrawal symptoms or a return of the original condition's symptoms (rebound effect).


Q: Are there any common foods or drinks that should be avoided while using Uniclar?

A: Official documentation for the nasal spray and topical formulations generally does not list specific foods or drinks that must be avoided. This is because the amount of medicine absorbed into the body from localized use is typically low. Consulting the patient information leaflet is recommended for specific warnings.


Q: Does Uniclar build up in the body over time?

A: Pharmacokinetic studies show that when Uniclar is used as directed, the amount of the drug absorbed into the bloodstream (systemic absorption) is described as low or negligible. This low systemic absorption suggests that the risk of accumulation in the body is generally considered minimal when the medicine is used as prescribed.


Q: Can Uniclar be taken with vitamins or common supplements like Vitamin D or magnesium?

A: Regulatory sources list known drug interactions primarily with medicines that affect the metabolism of Uniclar, such as potent CYP3A4 inhibitors. They typically do not list interactions with common vitamins or essential mineral supplements like Vitamin D or magnesium.


Q: Is it normal to feel a bit restless when first starting Uniclar?

A: Post-marketing surveillance for this class of medicine has occasionally included rare reports of central nervous system effects, such as a feeling of restlessness or psychomotor hyperactivity. If any unusual changes in mood or behavior are experienced, official product information provides guidance on seeking professional evaluation.


Q: Is there any concern about using Uniclar if I am trying to conceive?

A: Official regulatory documents advise that any use of the medicine should be determined after careful consideration of the potential benefits versus any potential fetal risk. This general guidance highlights the need for a professional review when planning conception.


Q: Does Uniclar interact with any common pain relievers like ibuprofen or acetaminophen?

A: The official documents focus on interactions with specific medicines, such as those that inhibit the CYP3A4 enzyme. Clinically significant interactions with common over-the-counter pain relievers like ibuprofen or acetaminophen are generally not reported in the regulatory label.


Q: Is Uniclar used in older adults?

A: Official labeling often includes a statement that the effectiveness of the medicine in geriatric patients (older adults) was studied in clinical trials. These studies typically found that no overall differences in response or safety profile were identified when compared to younger adult patients.


Q: Can Uniclar be used alongside herbal remedies?

A: Regulatory sections on drug interactions caution about interactions with known prescription medicines, especially those affecting drug metabolism. Since herbal remedies are highly varied, official information indicates that caution regarding potential unknown interactions should be considered when combined with Uniclar.


Q: Is it possible to become dependent on Uniclar?

A: While the term dependency is not used in regulatory warnings, prolonged or excessive use of any corticosteroid, including Uniclar, may lead to systemic effects like adrenal suppression. This condition can require the medicine to be stopped gradually rather than suddenly.


Q: Are there different brand names for the same medicine, Uniclar?

A: Yes, the active ingredient in Uniclar is Mometasone Furoate, and official drug information resources list that this compound is marketed globally under various brand names. These different names represent the same core medicine, and their use is guided by local authorization.


Q: Does taking Uniclar with food change how it works?

A: Regulatory pharmacokinetic studies examine whether a medicine's absorption is affected by the presence of food in the stomach. Official information for Uniclar specifies whether administration with or without food changes how the drug is absorbed into the system.


Q: Can I take Uniclar if I have high blood pressure?

A: Official documents list specific systemic conditions that may require caution during use. However, topical and intranasal corticosteroids are generally described as having a low systemic risk for most chronic conditions when used at the prescribed dose.


Q: Does the effectiveness of Uniclar decrease over time?

A: Clinical trial data addressing long-term efficacy track patient response over extended periods. This research examines whether the benefit is sustained or if there is evidence of reduced response, which is sometimes referred to as tachyphylaxis.


Q: Are there any specific lifestyle changes recommended when taking Uniclar?

A: Patient Information Leaflets typically contain any essential lifestyle advice that accompanies the medication. However, because Uniclar is a localized corticosteroid, official documents generally do not note major required changes to diet or daily routine.


Q: Is Uniclar a preventative medicine or a treatment?

A: Official sources describe the active ingredient, Mometasone Furoate, as functioning in a dual capacity. It can be used to prevent symptoms (prophylaxis) for certain chronic conditions as well as serving to treat existing inflammatory symptoms.


Q: What if I experience one of the rare side effects listed in the pamphlet?

A: Regulatory documents include clear instructions detailing the signs of a severe or rare adverse event. This information is provided to explain the circumstances under which professional evaluation may be necessary.


Q: Is there a generic version of Uniclar available?

A: Official product information resources confirm the marketing authorization status of the drug. These resources indicate whether generic alternatives containing the same active ingredient, Mometasone Furoate, have been approved and are available in the local market.


Q: Can Uniclar make me feel more anxious?

A: The official list of adverse reactions for this class of medicine has, in rare cases, included neuropsychiatric events. These events, such as anxiety, are typically listed as rare or very rare post-marketing occurrences.


Q: What does 'contraindicated' mean in relation to Uniclar?

A: Official patient resources commonly define a contraindication as a specific situation, condition, or disease in which the medicine should absolutely not be used. The drug is forbidden under these circumstances because the potential risk of harm outweighs any potential benefit.


Q: Are there known interactions between Uniclar and alcohol?

A: Official documentation from regulatory bodies contains a specific statement regarding the consumption of alcohol while using Uniclar. This statement outlines any known, clinically significant interactions between the medicine and alcohol.


Q: Does Uniclar affect laboratory test results, like blood work?

A: Regulatory labels may describe the potential for the medicine to interfere with laboratory test results, especially tests related to endocrine function due to its corticosteroid nature. However, such interference is typically rare with the low systemic absorption of Mometasone Furoate.


Q: Why are there different strengths of Uniclar available?

A: According to official regulatory documents, different strengths of the medicine are made available to accommodate specific needs. These variations are often required to adjust the dose for different age groups and to target varying conditions or severity levels.


Q: How long does it usually take for Uniclar to start making a difference?

A: Studies show that Uniclar's anti-inflammatory effect is dependent on a genomic mechanism that builds up gradually. The time to the onset of action is generally stated to be progressive, with the full therapeutic benefit building up over several days.


Q: Does the research show that Uniclar is effective for long-term use?

A: For chronic conditions, clinical trials provide data for extended periods, sometimes up to one year. This research structure aims to demonstrate that the measurements of symptom relief and patient-reported outcomes are sustained throughout the duration of use.


Q: Do you need to take Uniclar at the same time every day?

A: Patient information materials commonly instruct users to take the medication at approximately the same time each day. This consistent timing helps to maintain steady drug levels in the target tissue and is key for optimal adherence to the treatment protocol.


Q: Can people with liver issues use Uniclar?

A: Official regulatory documents state that use in patients with severe hepatic impairment (liver issues) requires caution. Due to the potential for increased drug exposure, official information may advise a dose modification or increased professional monitoring.


Q: Does Uniclar have any known long-term side effects?

A: Official documentation provides summaries of risks identified in both long-term clinical trials and post-marketing surveillance. These long-term risks may include potential effects on growth in children or certain ocular risks.


Q: What do clinical trial participants say about Uniclar?

A: Clinical study reports include measurements of patient-reported outcomes (PROs). These outcomes summarize the benefit perceived by participants, typically describing measurable improvements in symptom scores related to their condition.


Q: Is Uniclar designed to cure a condition or just manage symptoms?

A: The medicine’s described function as a glucocorticoid focuses on providing anti-inflammatory relief and relieving symptoms. This function is consistent with a role in managing the symptoms of a condition rather than providing a definitive cure.

How should Uniclar be stored and disposed of?

Storage Requirements for Uniclar (Mometasone Furoate)

Uniclar Nasal Spray must be stored at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F). It is essential to protect the medication from freezing and keep the container tightly closed when not in use. Store the product away from excessive heat, moisture, and direct light. As a safety precaution, the medicine must be stored out of the sight and reach of children.

Stability and Disposal Instructions

To ensure proper dosing, Uniclar has a limited period of use after opening; the product should be discarded 75 days after the date of first use. Disposal of unused or expired Uniclar should be managed through a drug take-back program. If this is not an option, the drug may be mixed with an undesirable substance, placed in a sealed bag, and disposed of with household trash, following all local waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Uniclar found in:

A-Z Index: